NVAX — Novavax Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $8.49
- 30-Day Move
- +26.0%
- Market Cap
- $1.5B
- Shares Outstanding
- 162,940,000
- P/E Ratio
- 3.49
- P/B Ratio
- 11.32
Novavax Inc
A read-only Alphactor snapshot for Novavax Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of 2026-04-21
Topline snapshot
Latest Close
$8.49
30-Day Move
+26.0%
Market Cap
$1.5B
Shares Outstanding
162,940,000
P/E Ratio
3.49
P/B Ratio
11.32
$8.49
+26.0%last 90 delayed daily bars
90D High
$11.97
90D Low
$6.36
Avg Volume
4,526,809
Gross margin is running at 93.5%, which gives a quick read on operating quality before you open the full model.
Net margin is 39.2%, useful for comparing NVAX against peers in Biotechnology.
NVAX is up 26.0% over the last 30 trading days shown on this page.
Latest operating income is $15M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$34.43
Rule of 40
42.4%
Latest Close
$8.49
30-Day Move
+26.0%
Market Cap
$1.5B
Shares Outstanding
162,940,000
P/E Ratio
3.49
P/B Ratio
11.32
ROE
-66.7%
ROA
-12.0%
Gross Margin
93.5%
Operating Margin
37.8%
Net Margin
39.2%
Debt / Equity
0.75
Current Ratio
0.98
Latest Revenue
$147M
Revenue
$147M
Gross Profit
$125M
Operating Income
$15M
Net Income
$18M
Gross Margin
9350.0%
Net Margin
3919.0%
Current Ratio
0.98
Debt / Equity
0.75
Fair Value
$34.43
Upside / Downside
+305.5%
Signal
Undervalued
Implied Growth
--
EV/Rev
$34.43
Growth Assumption
-10.0%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Altman Z
-1.71
Distress
Piotroski
5
Moderate (4-6)
Cash Conversion
-0.56x
Rule of 40
42.4%
Strong
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $1.6B | $-645M | $-658M | $-509M |
| 2023-12-31 | $556M | $-567M | $-545M | $-773M |
| 2024-12-31 | $682M | $-249M | $-187M | $-102M |
| 2025-12-31 | $1.1B | $551M | $440M | $-251M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Coatue Management
Filed 2026-02-17
--
--
Two Sigma Advisers
Filed 2025-11-14
--
--
BlackRock
Filed 2024-08-13
$150M
--
Vanguard Group
Filed 2025-11-07
$132M
-1.5%
D.E. Shaw
Filed 2026-02-17
$43M
+33.0%
Geode Capital Management
Filed 2025-11-12
$33M
+0.6%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.